Prostacyclin receptor regulation---from transcription to trafficking

Current Molecular Medicine

Volumn 11, Issue 7, 2011, Pages 517-527

  Midgett, C ^a   Stitham, J ^a   Martin, K A ^a   Hwa, J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Activation; Desensitization; Dimerization; Internalization; Prostacyclin receptor; Transcriptional regulation

Indexed keywords

7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ADENYLATE CYCLASE; ARACHIDONIC ACID; CICAPROST; COMPLEMENTARY DNA; CYCLIC AMP; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FORSKOLIN; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE TRIPHOSPHATASE; ILOPROST; PHOSPHODIESTERASE VI; PROSTACYCLIN; PROSTACYCLIN RECEPTOR; PROTEIN KINASE C; THROMBOXANE A2 RECEPTOR;

ATHEROSCLEROSIS; BRAIN ARTERY; CALCIUM TRANSPORT; CELL MIGRATION; CELL STRAIN HEK293; CELL STRAIN HEPG2; CELL SURFACE; CONFOCAL MICROSCOPY; CORONARY BLOOD VESSEL; DESENSITIZATION; DIMERIZATION; DISEASE COURSE; ENDOCYTOSIS; GLYCOSYLATION; HEART PROTECTION; HUMAN; IMMUNOPRECIPITATION; IN VIVO STUDY; INTERNALIZATION; ISCHEMIC HEART DISEASE; LIVER CELL CARCINOMA; MEGAKARYOCYTE; NEUROBLASTOMA CELL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PALMITOYLATION; PRENYLATION; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; REVIEW; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOGENESIS; TRANSCRIPTION REGULATION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

EID: 80054005346     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652411800615144     Document Type: Review

References (72)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart Disease and Stroke Statistics--2011 Update: A Report From the American Heart Association. Circulation 2011; 123(4): e18-e209.
2. Croce K, Libby P. Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol 2007; 14(1): 55-61.
3. Theilmeier G, Michiels C, Spaepen E, et al. Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia. Blood 2002; 99(12): 4486-93.
4. Massberg S, Brand K, Grüner S, et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002; 196(7): 887-96.
5. Grosser T, Bonisch D, Zucker TP, Schror K. Iloprost-induced inhibition of proliferation of coronary artery smooth muscle cells is abolished by homologous desensitization. Agents Actions Suppl 1995; 45: 85-91.
6. Zucker TP, Bonisch D, Hasse A, Grosser T, Weber AA, Schror K. Tolerance development to antimitogenic actions of prostacyclin but not of prostaglandin E1 in coronary artery smooth muscle cells. Eur J Pharmacol 1998; 345(2): 213-20.
7. Blindt R, Bosserhoff AK, vom Dahl J, et al. Activation of IP and EP(3) receptors alters cAMP-dependent cell migration. Eur J Pharmacol 2002; 444(1-2): 31-7.
8. O'Brien ER, Alpers CE, Stewart DK, et al. Proliferation in primary and restenotic coronary atherectomy tissue. Implications for antiproliferative therapy. Circ Res 1993; 73(2): 223-31.
9. Wilcox JN. Analysis of local gene expression in human atherosclerotic plaques. J Vasc Surg 1992; 15(5): 913-6.
10. Fetalvero KM, Shyu M, Nomikos AP, et al. The prostacyclin receptor induces human vascular smooth muscle cell differentiation via the protein kinase A pathway. Am J Physiol Heart Circ Physiol 2006; 290(4): H1337-46.
11. Kasza Z, Fetalvero KM, Ding M, et al. Novel signaling pathways promote a paracrine wave of prostacyclin-induced vascular smooth muscle differentiation. J Mol Cell Cardiol 2009; 46(5): 682-94.
12. Arehart E, Stitham J, Asselbergs FW, et al. Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. Circ Res 2008; 102(8): 986-93.
13. Egan KM, Lawson JA, Fries S, et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 2004; 306(5703): 1954-7.
14. Kobayashi T, Tahara Y, Matsumoto M, et al. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 2004; 114(6): 784-94.
15. Gryglewski RJ. Prostacyclin among prostanoids. Pharmacol Rep 2008; 60(1): 3-11.
16. Boie Y, Rushmore TH, Darmon-Goodwin A, et al. Cloning and expression of a cDNA for the human prostanoid IP receptor. J Biol Chem 1994; 269(16): 12173-8.
17. Kobayashi T, Ushikubi F, Narumiya S. Amino acid residues conferring ligand binding properties of prostaglandin I and prostaglandin D receptors. Identification by site-directed mutagenesis. J Biol Chem 2000; 275(32): 24294-303.
18. Smyth EM, FitzGerald GA. Human prostacyclin receptor. Vitam Horm 2002; 65: 149-65.
19. Stitham J, Stojanovic A, Merenick BL, O'Hara KA, Hwa J. The unique ligand-binding pocket for the human prostacyclin receptor. Site-directed mutagenesis and molecular modeling. J Biol Chem 2003; 278(6): 4250-7.
20. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999; 79(4): 1193-226.
21. Reid HM, Mulvaney EP, Turner EC, Kinsella BT. Interaction of the human prostacyclin receptor with Rab11: characterization of a novel Rab11 binding domain within alpha-helix 8 that is regulated by palmitoylation. J Biol Chem 2010; 285(24): 18709-26.
22. Zhang Z, Austin SC, Smyth EM. Glycosylation of the human prostacyclin receptor: role in ligand binding and signal transduction. Mol Pharmacol 2001; 60(3): 480-7.
23. Stitham J, Gleim SR, Douville K, Arehart E, Hwa J. Versatility and differential roles of cysteine residues in human prostacyclin receptor structure and function. J Biol Chem 2006; 281(48): 37227-36.
24. Hayes JS, Lawler OA, Walsh MT, Kinsella BT. The prostacyclin receptor is isoprenylated. Isoprenylation is required for efficient receptor-effector coupling. Journal of Biological Chemistry 1999; 274(34): 23707-18.
25. Miggin SM, Lawler OA, Kinsella BT. Investigation of a functional requirement for isoprenylation by the human prostacyclin receptor. Eur J Biochem 2002; 269(6): 1714-25.
26. Miggin SM, Lawler OA, Kinsella BT. Palmitoylation of the human prostacyclin receptor. Functional implications of palmitoylation and isoprenylation. J Biol Chem 2003; 278(9): 6947-58.
27. Turner EC, Kinsella BT. Transcriptional regulation of the human prostacyclin receptor gene is dependent on Sp1, PU.1 and Oct-1 in megakaryocytes and endothelial cells. J Mol Biol 2009; 386(3): 579-97.
28. Turner EC, Kinsella BT. Estrogen increases expression of the human prostacyclin receptor within the vasculature through an ERalpha-dependent mechanism. J Mol Biol 2010; 396(3): 473-86.
29. Wettschureck N, Offermanns S. Mammalian G proteins and their cell type specific functions. Physiol Rev 2005; 85(4): 1159-204.
30. Siehler S. Regulation of RhoGEF proteins by G12/13- coupled receptors. Br J Pharmacol 2009; 158(1): 41-9.
31. Miggin SM, Kinsella BT. Investigation of the mechanisms of G protein: effector coupling by the human and mouse prostacyclin receptors. Identification of critical speciesdependent differences. J Biol Chem 2002; 277(30): 27053-64.
32. Smyth EM, Nestor PV, FitzGerald GA. Agonist-dependent phosphorylation of an epitope-tagged human prostacyclin receptor. J Biol Chem 1996; 271(52): 33698-704.
33. Smyth EM, Li WH, FitzGerald GA. Phosphorylation of the prostacyclin receptor during homologous desensitization. A critical role for protein kinase c. J Biol Chem 1998; 273(36): 23258-66.
34. Kam Y, Chow KB, Wise H. Factors affecting prostacyclin receptor agonist efficacy in different cell types. Cell Signal 2001; 13(11): 841-7.
35. Vassaux G, Gaillard D, Ailhaud G, Negrel R. Prostacyclin is a specific effector of adipose cell differentiation. Its dual role as a cAMP-and Ca(2+)-elevating agent. J Biol Chem 1992; 267(16): 11092-7.
36. Parfenova H, Zuckerman S, Leffler CW. Inhibitory effect of indomethacin on prostacyclin receptor-mediated cerebral vascular responses. Am J Physiol 1995; 268(5 Pt 2): H1884-90.
37. Nishimura T, Yamamoto T, Komuro Y, Hara Y. Antiplatelet functions of a stable prostacyclin analog, SM-10906 are exerted by its inhibitory effect on inositol 1,4,5-trisphosphate production and cytosolic Ca++ increase in rat platelets stimulated by thrombin. Thromb Res 1995; 79(3): 307-17.
38. Zhang L, Bastepe M, Jüppner H, Ruan K-H. Characterization of the molecular mechanisms of the coupling between intracellular loops of prostacyclin receptor with the C-terminal domain of the Galphas protein in human coronary artery smooth muscle cells. Arch Biochem Biophys 2006; 454(1): 80-8.
39. Zhang L, Huang G, Wu J, Ruan KH. A profile of the residues in the first intracellular loop critical for Gs-mediated signaling of human prostacyclin receptor characterized by an integrative approach of NMR-experiment and mutagenesis. Biochemistry 2005; 44(34): 11389-401.
40. Zhang L, Wu J, Ruan K-H. Solution structure of the first intracellular loop of prostacyclin receptor and implication of its interaction with the C-terminal segment of G alpha s protein. Biochemistry 2006;45(6): 1734-44.
41. Scheerer P, Park JH, Hildebrand PW, et al. Crystal structure of opsin in its G-protein-interacting conformation. Nature 2008; 455(7212): 497-502.
42. Choe HW, Kim YJ, Park JH, et al. Crystal structure of metarhodopsin II. Nature 2011; 471(7340): 651-5.
43. Kelly E, Bailey CP, Henderson G. Agonist-selective mechanisms of GPCR desensitization. British Journal of Pharmacology 2008; 153: S379-88.
44. Ferguson SSG. Phosphorylation-independent attenuation of GPCR signalling. Trends Pharmacol Sci 2007; 28(4): 173-9.
45. Smyth EM, Li WH, FitzGerald GA. Phosphorylation of the prostacyclin receptor during homologous desensitization. A critical role for protein kinase C. J Biol Chem 1998; 273(36): 23258-66.
46. Nilius SM, Hasse A, Kuger P, Schrör K, Meyer-Kirchrath J. Agonist-induced long-term desensitization of the human prostacyclin receptor. FEBS Letters 2000; 484(3): 211-6.
47. Fisch A, Tobusch K, Veit K, Meyer J, Darius H. Prostacyclin receptor desensitization is a reversible phenomenon in human platelets. Circulation 1997; 96(3): 756-60.
48. Jaschonek K, Faul C, Schmidt H, Renn W. Desensitization of platelets to iloprost. Loss of specific binding sites and heterologous desensitization of adenylate cyclase. Eur J Pharmacol. 1988; 147(2): 187-96.
49. Nishimura T, Yamamoto T, Komuro Y, Hara Y. Antiplatelet functions of a stable prostacyclin analog, SM-10906 are exerted by its inhibitory effect on inositol 1,4,5-trisphosphate production and cytosolic Ca++ increase in rat platelets stimulated by thrombin. Thromb Res 1995; 79(3): 307-17.
50. Harper MT, Poole AW. Diverse functions of protein kinase C isoforms in platelet activation and thrombus formation. J Thromb Haemost 2010; 8(3): 454-62.
51. Ashby B. Novel mechanism of heterologous desensitization of adenylate cyclase: prostaglandins bind with different affinities to both stimulatory and inhibitory receptors on platelets. Biochem Pharmacol 1990; 38(1): 46-53.
52. Luttrell LM, Lefkowitz RJ. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci 2002; 115(Pt 3): 455-65.
53. Shenoy SK, Lefkowitz RJ. Multifaceted roles of beta-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling. Biochem J 2003; 375(Pt 3): 503-15.
54. Smyth EM, Austin SC, Reilly MP, FitzGerald GA. Internalization and sequestration of the human prostacyclin receptor. J Biol Chem 2000; 275(41): 32037-45.
55. Seachrist JL, Ferguson SSG. Regulation of G proteincoupled receptor endocytosis and trafficking by Rab GTPases. Life Sci 2003; 74(2-3): 225-35.
56. O'Keeffe MB, Reid HM, Kinsella BT. Agonist-dependent internalization and trafficking of the human prostacyclin receptor: a direct role for Rab5a GTPase. Biochim Biophys Acta 2008; 1783(10): 1914-28.
57. Wikström K, Reid HM, Hill M, et al. Recycling of the human prostacyclin receptor is regulated through a direct interaction with Rab11a GTPase. Cell Signal 2008; 20(12): 2332-46.
58. Nancy V, Callebaut I, El Marjou A, de Gunzburg J. The delta subunit of retinal rod cGMP phosphodiesterase regulates the membrane association of Ras and Rap GTPases. J Biol Chem 2002; 277(17): 15076-84.
59. Wilson SJ, Smyth EM. Internalization and recycling of the human prostacyclin receptor is modulated through its isoprenylation-dependent interaction with the delta subunit of cGMP phosphodiesterase 6. J Biol Chem 2006; 281(17): 11780-6.
60. Giovanazzi S, Accomazzo MR, Letari O, Oliva D, Nicosia S. Internalization and down-regulation of the prostacyclin receptor in human platelets. Biochem J 1997; 325 (Pt 1): 71-7.
61. Donnellan PD, Kinsella BT. Immature and mature species of the human Prostacyclin Receptor are ubiquitinated and targeted to the 26S proteasomal or lysosomal degradation pathways, respectively. J Mol Signal 2009; 4: 7.
62. Marchese A, Raiborg C, Santini F, Keen JH, Stenmark H, Benovic JL. The E3 ubiquitin ligase AIP4 mediates ubiquitination and sorting of the G protein-coupled receptor CXCR4. Dev Cell 2003; 5(5): 709-22.
63. Cottrell GS, Padilla B, Pikios S, et al. Ubiquitin-dependent down-regulation of the neurokinin-1 receptor. J Biol Chem 2006; 281(38): 27773-83.
64. Martin NP, Lefkowitz RJ, Shenoy SK. Regulation of V2 vasopressin receptor degradation by agonist-promoted ubiquitination. J Biol Chem 2003; 278(46): 45954-9.
65. Milligan G. G protein-coupled receptor dimerization: function and ligand pharmacology. Mol Pharmacol 2004; 66(1): 1-7.
66. Lohse MJ. Dimerization in GPCR mobility and signaling. Curr Opin Pharmacol 2010; 10(1): 53-8.
67. Giguere V, Gallant MA, de Brum-Fernandes AJ, Parent JL. Role of extracellular cysteine residues in dimerization/oligomerization of the human prostacyclin receptor. Eur J Pharmacol 2004; 494(1): 11-22.
68. Ibrahim S, Tetruashvily M, Frey AJ, et al. Dominant negative actions of human prostacyclin receptor variant through dimerization: implications for cardiovascular disease. Arterioscler Thromb Vasc Biol 2010; 30(9): 1802-9.
69. Wilson SJ, Roche AM, Kostetskaia E, Smyth EM. Dimerization of the human receptors for prostacyclin and thromboxane facilitates thromboxane receptor-mediated cAMP generation. J Biol Chem 2004; 279(51): 53036-47.
70. Shen RF, Tai HH. Thromboxanes: synthase and receptors. J Biomed Sci 1998; 5(3): 153-72.
71. Kinsella BT, O'Mahony DJ, Fitzgerald GA. The human thromboxane A2 receptor alpha isoform (TP alpha) functionally couples to the G proteins Gq and G11 in vivo and is activated by the isoprostane 8-epi prostaglandin F2 alpha. J Pharmacol Exp Ther 1997; 281(2): 957-64.
72. Wilson SJ, Dowling JK, Zhao L, Carnish E, Smyth EM. Regulation of thromboxane receptor trafficking through the prostacyclin receptor in vascular smooth muscle cells: role of receptor heterodimerization. Arterioscler Thromb Vasc Biol 2007; 27(2): 290-6.